Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Net Cash Flow (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Net Cash Flow for 7 consecutive years, with $594339.0 as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 106.44% to $594339.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, up 118.7% year-over-year, with the annual reading at -$6.8 million for FY2025, 19.14% up from the prior year.
  • Net Cash Flow for Q4 2025 was $594339.0 at Outlook Therapeutics, up from -$817729.0 in the prior quarter.
  • The five-year high for Net Cash Flow was $1.9 million in Q1 2025, with the low at -$9.2 million in Q4 2024.